ALIN Foundation Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ALIN Foundation's estimated annual revenue is currently $620k per year.(i)
  • ALIN Foundation's estimated revenue per employee is $155,000

Employee Data

  • ALIN Foundation has 4 Employees.(i)
  • ALIN Foundation grew their employee count by -20% last year.

ALIN Foundation's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is ALIN Foundation?

Established in 1962 by Dr. Kenneth Matsumura, ALIN Foundation is the oldest bio-tech organization in the world. During our half a century of remarkable achievements, ALIN Foundation has developed lifesaving treatments for the four diseases responsible for the most deaths in the world — heart attack, cancer, diabetes, and liver failure. Each of these developments represents a stunning breakthrough in its field. ALIN Foundation is best known for these 4 medical advancements: The Bio-Artificial Liver, a device is designed to be used outside the body to sustain patients who are suffering from liver failure due to hepatitis, cirrhosis, or cancer. The Bio-Artifical Pancreas, a device that maintains normal blood sugar levels in diabetics. Side Effect-Free Chemotherapy ("Safe" Chemo), a cancer therapy that when used in conjunction with chemotherapy negates the side effects commonly associated with chemotherapy. The HeartAlarm Wristwatch, a watch designed to warn its wearer an hour or more before a heart attack occurs.

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.5M4-33%N/A
#2
$0.3M4-60%N/A
#3
$0.4M4N/AN/A
#4
$1.7M40%N/A
#5
$0.3M4-20%N/A